IL152726A0 - Adenosine a2a receptor antagonists - Google Patents

Adenosine a2a receptor antagonists

Info

Publication number: IL152726A0
Authority: IL; Israel
Prior art keywords: adenosine; receptor antagonists; antagonists; receptor
Prior art date: 2000-05-26

Application number

IL15272601A

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-26

Filing date

2001-05-24

Publication date

2003-06-24

2001-05-24 Application filed by Schering Corp filed Critical Schering Corp

2003-06-24 Publication of IL152726A0 publication Critical patent/IL152726A0/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IL15272601A 2000-05-26 2001-05-24 Adenosine a2a receptor antagonists IL152726A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20714300P	2000-05-26	2000-05-26
PCT/US2001/016954 WO2001092264A1 (en)	2000-05-26	2001-05-24	Adenosine a2a receptor antagonists

Publications (1)

Publication Number	Publication Date
IL152726A0 true IL152726A0 (en)	2003-06-24

Family

ID=22769372

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL15272601A IL152726A0 (en)	2000-05-26	2001-05-24	Adenosine a2a receptor antagonists
IL152726A IL152726A (en)	2000-05-26	2002-11-10	5-AMINO-{PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE}-2- AND 7-SUBSTITUTED DERIVATIVES AS ADENOSINE A2A RECEPTOR INHIBITORS
IL220174A IL220174A (en)	2000-05-26	2012-06-04	Acid addition salts of 2- and 7-substituted derivatives of 5-amino-{pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine} and pharmaceutical compositions comprising them

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL152726A IL152726A (en)	2000-05-26	2002-11-10	5-AMINO-{PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE}-2- AND 7-SUBSTITUTED DERIVATIVES AS ADENOSINE A2A RECEPTOR INHIBITORS
IL220174A IL220174A (en)	2000-05-26	2012-06-04	Acid addition salts of 2- and 7-substituted derivatives of 5-amino-{pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine} and pharmaceutical compositions comprising them

Country Status (31)

Country	Link
US (4)	US6630475B2 (en)
EP (1)	EP1283839B1 (en)
JP (3)	JP4574112B2 (en)
KR (1)	KR100520907B1 (en)
CN (2)	CN100384847C (en)
AR (1)	AR028621A1 (en)
AT (1)	ATE293627T1 (en)
AU (2)	AU6808901A (en)
BR (1)	BRPI0111015B8 (en)
CA (1)	CA2410237C (en)
CZ (1)	CZ303790B6 (en)
DE (1)	DE60110219T2 (en)
DK (1)	DK1283839T3 (en)
EC (1)	ECSP024364A (en)
ES (1)	ES2237576T3 (en)
HK (1)	HK1049007B (en)
HU (1)	HU230420B1 (en)
IL (3)	IL152726A0 (en)
MX (1)	MXPA02011625A (en)
MY (1)	MY132006A (en)
NO (1)	NO325008B1 (en)
NZ (1)	NZ522326A (en)
PE (1)	PE20020062A1 (en)
PL (1)	PL218764B1 (en)
PT (1)	PT1283839E (en)
RU (1)	RU2315053C2 (en)
SI (1)	SI1283839T1 (en)
SK (1)	SK287748B6 (en)
TW (1)	TWI288137B (en)
WO (1)	WO2001092264A1 (en)
ZA (1)	ZA200208898B (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI288137B (en) *	2000-05-26	2007-10-11	Schering Corp	Adenosine A2a receptor antagonists
MXPA04002389A (en) *	2001-09-13	2004-05-31	Schering Corp	Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic.
KR100687954B1 (en)	2001-10-15	2007-02-27	쉐링 코포레이션	Imidazo?4,3-e?-1,2,4-triazolo?1,5-c? pyrimidines as adenosine A2a receptor antagonists
FR2832405B1 (en) *	2001-11-19	2004-12-10	Sanofi Synthelabo	TETRAHYDROPYRIDYL-ALKYL-HETEROCYCLES NITROGEN, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2336435T3 (en) *	2001-11-30	2010-04-13	Schering Corporation	ADENOSINE A2A RECEIVER ANTAGONIST.
HUP0402324A3 (en)	2001-11-30	2008-09-29	Schering Corp	[1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
PE20030739A1 (en)	2001-11-30	2003-08-28	Schering Corp	ADENOSINE A2A RECEPTOR ANTAGONISTS
BR0306919A (en)	2002-01-28	2004-11-09	Kyowa Hakko Kogyo Kk	Methods for reducing or suppressing the adverse effectiveness of l-dopa and / or dopamine agonist therapy, and for moderate l-dopa treatment, composition for moderate l-dopa treatment, method for treating parkinson's disease and / or complications. -dopa motors, composition for the treatment of parkinson's disease, and methods for prolonging the effective treatment of parkinson's disease, and for treating movement disorders
US7064204B2 (en) *	2002-05-30	2006-06-20	King Pharmacueticals Reserch And Development, Inc.	Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US20060106040A1 (en) *	2002-12-19	2006-05-18	Michael Grzelak	Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CN101310724A (en) *	2002-12-19	2008-11-26	先灵公司	Uses of adenosine a2alpha receptor antagonists
WO2004092172A2 (en)	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
CN100503609C (en) *	2003-04-23	2009-06-24	先灵公司	2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2, 4-triazolo [1,5-c]-pyrimidine adenosine A2areceptor antagonist
JP4778894B2 (en) *	2003-06-10	2011-09-21	協和発酵キリン株式会社	How to treat anxiety disorders
EP1636187A1 (en) *	2003-06-12	2006-03-22	Novo Nordisk A/S	Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
CA2541989C (en) *	2003-10-24	2013-10-01	Exelixis, Inc.	P70s6 kinase modulators and method of use
DE602004004677T2 (en)	2003-10-28	2007-11-15	Schering Corp.	Process for the preparation of substituted 5-amino-pyrazolo (4,3-E) -1,2,4-triazolo (1,5-C) pyrimidines
ATE377599T1 (en) *	2003-12-01	2007-11-15	Schering Corp	METHOD FOR PRODUCING SUBSTITUTED 5-AMINOPYRAZOLO(4,3-E)-1,2,4-TRIAZOLO(1,5-C)PYRIMIDINES
CA2550071A1 (en) *	2003-12-19	2005-07-07	Schering Corporation	Pharmaceutical compositions
DE602005020127D1 (en) *	2004-04-21	2010-05-06	Schering Corp	PYRAZOLOÄ4,3-EÜ-1,2,4-TRIAZOLOÄ1,5-CÜPYRIMIDINE AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR
ATE556712T1 (en) *	2005-06-07	2012-05-15	Kyowa Hakko Kirin Co Ltd	A2A ANTAGONISTS FOR THE TREATMENT OF MOTOR DISORDERS
CA2622741A1 (en) *	2005-09-19	2007-03-29	Schering Corporation	2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
PE20070521A1 (en) *	2005-09-23	2007-07-13	Schering Corp	7- [2- [4- (6-FLUORO-3-METHYL-1,2-BENZYSOXAZOL-5-IL) -1-PIPERAZINYL] ETHYL] -2- (1-PROPINYL) -7H-PIRAZOLE- [4, 3-E] - [1,2,4] -TRIAZOL- [1,5-C] -PYRIMIDIN-5-AMINE AS ANTAGONIST OF THE ADENOSINE A2a RECEPTOR
ES2273599B1 (en)	2005-10-14	2008-06-01	Universidad De Barcelona	COMPOUNDS FOR THE TREATMENT OF HEADPHONE FIBRILATION.
US20090298878A1 (en) *	2006-07-14	2009-12-03	Akira Matsumura	Oxime compounds and the use thereof
TW200840566A (en) *	2006-12-22	2008-10-16	Esteve Labor Dr	Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
US7691869B2 (en) *	2007-03-30	2010-04-06	King Pharmaceuticals Research And Development, Inc.	Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
WO2009110955A2 (en) *	2008-02-29	2009-09-11	Albert Einstein College Of Medicine Of Yeshiva University	Ketoconazole-derivative antagonists of human pregnane x receptor and uses thereof
CA2717172A1 (en)	2008-03-04	2009-09-11	Schering Corporation	1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
CN102014959B (en)	2008-03-10	2016-01-20	康奈尔大学	The adjustment of blood-brain barrier permeability
TWI473614B (en)	2008-05-29	2015-02-21	Kyowa Hakko Kirin Co Ltd	Anti-analgesic inhibitors
ES2658892T3 (en) *	2008-07-23	2018-03-12	Kyowa Hakko Kirin Co., Ltd.	Therapeutic agent for migraine
US20100093702A1 (en) *	2008-10-13	2010-04-15	Barbay J Kent	METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
CA2748174A1 (en)	2008-12-30	2010-07-08	Arqule, Inc.	Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
CA2750265A1 (en)	2009-01-20	2010-07-29	Marc Cantillon	Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
US8993808B2 (en)	2009-01-21	2015-03-31	Oryzon Genomics, S.A.	Phenylcyclopropylamine derivatives and their medical use
WO2010103547A2 (en)	2009-03-13	2010-09-16	Advinus Therapeutics Private Limited	Substituted fused pyrimidine compounds
WO2010114894A1 (en)	2009-03-31	2010-10-07	Arqule, Inc.	Substituted heterocyclic compounds
WO2010147941A1 (en)	2009-06-15	2010-12-23	Marvell World Trade Ltd.	System and methods for gamut bounded saturation adaptive color enhancement
US8598343B2 (en)	2009-08-07	2013-12-03	Merck Sharp & Dohme Corp.	Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
CA2812683C (en)	2009-09-25	2017-10-10	Oryzon Genomics S.A.	Lysine specific demethylase-1 inhibitors and their use
WO2011042217A1 (en)	2009-10-09	2011-04-14	Oryzon Genomics S.A.	Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011101861A1 (en)	2010-01-29	2011-08-25	Msn Laboratories Limited	Process for preparation of dpp-iv inhibitors
WO2011106573A2 (en)	2010-02-24	2011-09-01	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en)	2010-02-24	2017-04-11	Oryzon Genomics, S.A.	Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
DK2560947T3 (en)	2010-04-19	2016-11-21	Oryzon Genomics Sa	LYSINE-SPECIFIC demethylase-1 INHIBITORS AND THEIR USE
LT2598482T (en)	2010-07-29	2018-07-10	Oryzon Genomics, S.A.	Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
WO2012013727A1 (en)	2010-07-29	2012-02-02	Oryzon Genomics S.A.	Cyclopropylamine derivatives useful as lsd1 inhibitors
JP5843869B2 (en) *	2010-09-24	2016-01-13	アドヴィナス・セラピューティックス・リミテッド	Condensed tricyclic compounds as adenosine receptor antagonists
US9061966B2 (en)	2010-10-08	2015-06-23	Oryzon Genomics S.A.	Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en)	2010-11-30	2012-06-07	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en)	2011-02-08	2021-11-24	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for myeloproliferative disorders
WO2012127472A1 (en) *	2011-03-22	2012-09-27	Mapi Pharma Ltd.	Process and intermediates for the preparation of preladenant and related compounds
WO2012129381A1 (en) *	2011-03-22	2012-09-27	Concert Pharmaceuticals Inc.	Deuterated preladenant
WO2013024474A1 (en) *	2011-08-18	2013-02-21	Mapi Phrarma Ltd.	Polymorphs of preladenant
WO2013057322A1 (en)	2011-10-20	2013-04-25	Oryzon Genomics, S.A.	(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
BR112014009306B1 (en)	2011-10-20	2021-07-20	Oryzon Genomics S.A.	(HETERO)ARIL CYCLOPROPILAMINE COMPOUNDS AS LSD1 INHIBITORS
WO2014071512A1 (en) *	2012-11-06	2014-05-15	Universite Laval	Combination therapy and methods for the treatment of respiratory diseases
WO2014101120A1 (en)	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US10472347B2 (en)	2014-11-18	2019-11-12	Merck Sharp & Dohme Corp.	Aminopyrazine compounds with A2A antagonist properties
US10138212B2 (en)	2015-02-06	2018-11-27	Merck Sharp & Dohme Corp.	Aminoquinazoline compounds as A2A antagonist
US10688082B2 (en)	2015-06-11	2020-06-23	Merck Sharp & Dohme Corp.	Aminopyrazine compounds with A2A antagonist properties
WO2017008205A1 (en)	2015-07-10	2017-01-19	Merck Sharp & Dohme Corp.	Substituted aminoquinazoline compounds as a2a antagonist
US9675585B1 (en)	2016-03-24	2017-06-13	Ezra Pharma	Extended release pharmaceutical formulations
US9687475B1 (en)	2016-03-24	2017-06-27	Ezra Pharma Llc	Extended release pharmaceutical formulations with controlled impurity levels
TWI801372B (en) *	2017-03-30	2023-05-11	比利時商艾特歐斯比利時有限公司	Thiocarbamate derivatives as a2a inhibitors and methods for use in the treatment of cancers
HRP20221039T1 (en) *	2017-03-30	2022-11-11	iTeos Belgium SA	2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
EP3723754A4 (en)	2017-12-13	2021-05-19	Merck Sharp & Dohme Corp.	Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
CA3087655A1 (en)	2018-01-04	2019-07-11	Impetis Biosciences Ltd.	Tricyclic compounds, compositions and medicinal applications thereof
CR20200441A (en)	2018-02-27	2021-03-15	Incyte Corp	Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CN108276345A (en) *	2018-03-22	2018-07-13	重庆奥舍生物化工有限公司	A kind of preparation method of pharmaceutical intermediate pyrimidine -5-formaldehyde
AU2019251148A1 (en) *	2018-04-08	2020-10-22	Beigene, Ltd.	Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist
MX2020012376A (en)	2018-05-18	2021-03-09	Incyte Corp	Fused pyrimidine derivatives as a2a / a2b inhibitors.
CN108864114B (en)	2018-06-04	2020-11-06	应世生物科技(南京)有限公司	Selectivity A2AReceptor antagonists
CA3105721A1 (en)	2018-07-05	2020-01-09	Incyte Corporation	Fused pyrazine derivatives as a2a / a2b inhibitors
CN110742893B (en) *	2018-07-23	2024-04-05	百济神州(北京)生物科技有限公司	Methods of treating cancer with A2A receptor antagonists
WO2020112700A1 (en)	2018-11-30	2020-06-04	Merck Sharp & Dohme Corp.	9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
CR20210336A (en)	2018-12-20	2021-12-06	Incyte Corp	Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
TWI829857B (en)	2019-01-29	2024-01-21	美商英塞特公司	Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2020227156A1 (en) *	2019-05-03	2020-11-12	Nektar Therapeutics	Adenosine 2 receptor antagonists
DE102019116986A1 (en)	2019-06-24	2020-12-24	Helmholtz-Zentrum Dresden-Rossendorf E. V.	Deuterated 7- (3- (4- (2 - ([18F] fluoro) ethoxy) phenyl) propyl) -2- (furan-2-yl) -7H-pyrazolo [4,3-e] [1,2, 4] triazolo [1,5-c] pyrimidin-5-amine derivatives
JP2022540583A (en) *	2019-07-17	2022-09-16	テオンセラピューティクス，インク．	Adenosine A2A receptor antagonist and use thereof
CN112625050B (en)	2019-07-30	2021-10-01	杭州阿诺生物医药科技有限公司	Preparation method of A2A and/or A2B receptor inhibitor
CN112479956A (en)	2019-07-30	2021-03-12	杭州阿诺生物医药科技有限公司	Method for preparing adenosine receptor inhibitor intermediate
CN111072675A (en) *	2019-12-12	2020-04-28	广东东阳光药业有限公司	Nitrogen-containing fused tricyclic derivatives and uses thereof
JP7431665B2 (en)	2020-05-20	2024-02-15	Ykk Ap株式会社	Joint structure and fittings
CN113773327B (en) *	2021-09-13	2022-07-15	八叶草健康产业研究院(厦门)有限公司	Preparation method of pyrazolopyrimidinyltriazole ring compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU466232A1 (en) *	1973-05-23	1975-04-05	Киевский Ордена Ленина Государственный Университет Им.Т.Г.Шевченко	The method of obtaining condensed pyrimido-triazinium compounds with bridging nitrogen atoms
EP0217748B1 (en)	1985-09-30	1991-02-06	Ciba-Geigy Ag	2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
SU1739850A3 (en) *	1987-08-31	1992-06-07	Такеда Кемикал Индастриз, Лтд (Фирма)	Method for synthesis of condensed derivatives of pyrazolo-[3,4-d]-pyrimidine
IT1264901B1 (en) *	1993-06-29	1996-10-17	Schering Plough S P A	HETEROCYCLIC ANALOGUES OF 1,2,4-TRIAZOLE(15-C)PYRIMIDINES WITH ANTAGONIST ACTIVITY FOR THE ADENOSINE A2 RECEPTOR
CA2144330A1 (en)	1993-07-27	1995-02-09	Fumio Suzuki	A therapeutic agent for parkinson's disease
IT1277392B1 (en) *	1995-07-28	1997-11-10	Schering Plough S P A	HEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C] PYRIMIDINE WITH ANTAGONIST ACTIVITY FOR THE A2A RECEPTOR OF ADENOSINE
IT1291372B1 (en) *	1997-05-21	1999-01-07	Schering Plough S P A	USE OF HETEROCYCLIC ANALOGS OF 1,2,4-TRIAZOLE (1,5-C) PYRIMIDINS FOR THE PREPARATION OF MEDICATIONS USEFUL FOR THE TREATMENT OF DISEASES
TWI288137B (en) *	2000-05-26	2007-10-11	Schering Corp	Adenosine A2a receptor antagonists
ES2336435T3 (en) *	2001-11-30	2010-04-13	Schering Corporation	ADENOSINE A2A RECEIVER ANTAGONIST.
CN101310724A (en) *	2002-12-19	2008-11-26	先灵公司	Uses of adenosine a2alpha receptor antagonists
DE602004004677T2 (en) *	2003-10-28	2007-11-15	Schering Corp.	Process for the preparation of substituted 5-amino-pyrazolo (4,3-E) -1,2,4-triazolo (1,5-C) pyrimidines
ATE377599T1 (en) *	2003-12-01	2007-11-15	Schering Corp	METHOD FOR PRODUCING SUBSTITUTED 5-AMINOPYRAZOLO(4,3-E)-1,2,4-TRIAZOLO(1,5-C)PYRIMIDINES
DE602005020127D1 (en) *	2004-04-21	2010-05-06	Schering Corp	PYRAZOLOÄ4,3-EÜ-1,2,4-TRIAZOLOÄ1,5-CÜPYRIMIDINE AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR
CA2622741A1 (en) *	2005-09-19	2007-03-29	Schering Corporation	2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists

2001
- 2001-05-24 TW TW090112461A patent/TWI288137B/en not_active IP Right Cessation
- 2001-05-24 WO PCT/US2001/016954 patent/WO2001092264A1/en active Application Filing
- 2001-05-24 DK DK01945991T patent/DK1283839T3/en active
- 2001-05-24 AU AU6808901A patent/AU6808901A/en active Pending
- 2001-05-24 DE DE60110219T patent/DE60110219T2/en not_active Expired - Lifetime
- 2001-05-24 EP EP01945991A patent/EP1283839B1/en not_active Expired - Lifetime
- 2001-05-24 ES ES01945991T patent/ES2237576T3/en not_active Expired - Lifetime
- 2001-05-24 MY MYPI20012466A patent/MY132006A/en unknown
- 2001-05-24 MX MXPA02011625A patent/MXPA02011625A/en active IP Right Grant
- 2001-05-24 CN CNB2006100049297A patent/CN100384847C/en not_active Expired - Lifetime
- 2001-05-24 AT AT01945991T patent/ATE293627T1/en active
- 2001-05-24 US US09/865,071 patent/US6630475B2/en not_active Ceased
- 2001-05-24 PL PL360472A patent/PL218764B1/en unknown
- 2001-05-24 KR KR10-2002-7015699A patent/KR100520907B1/en active IP Right Grant
- 2001-05-24 NZ NZ522326A patent/NZ522326A/en not_active IP Right Cessation
- 2001-05-24 JP JP2002500877A patent/JP4574112B2/en not_active Expired - Lifetime
- 2001-05-24 PT PT01945991T patent/PT1283839E/en unknown
- 2001-05-24 SK SK1671-2002A patent/SK287748B6/en not_active IP Right Cessation
- 2001-05-24 PE PE2001000475A patent/PE20020062A1/en active IP Right Grant
- 2001-05-24 CN CNB018134491A patent/CN1247588C/en not_active Expired - Lifetime
- 2001-05-24 CZ CZ20023886A patent/CZ303790B6/en not_active IP Right Cessation
- 2001-05-24 CA CA002410237A patent/CA2410237C/en not_active Expired - Lifetime
- 2001-05-24 SI SI200130336T patent/SI1283839T1/xx unknown
- 2001-05-24 HU HU0600239A patent/HU230420B1/en unknown
- 2001-05-24 RU RU2002135620/04A patent/RU2315053C2/en active
- 2001-05-24 AR ARP010102483A patent/AR028621A1/en active IP Right Grant
- 2001-05-24 AU AU2001268089A patent/AU2001268089C1/en not_active Expired
- 2001-05-24 BR BRPI0111015-2 patent/BRPI0111015B8/en not_active IP Right Cessation
- 2001-05-24 IL IL15272601A patent/IL152726A0/en unknown
2002
- 2002-11-01 ZA ZA200208898A patent/ZA200208898B/en unknown
- 2002-11-10 IL IL152726A patent/IL152726A/en active IP Right Grant
- 2002-11-25 EC EC2002004364A patent/ECSP024364A/en unknown
- 2002-11-25 NO NO20025651A patent/NO325008B1/en not_active IP Right Cessation
2003
- 2003-02-21 HK HK03101315.3A patent/HK1049007B/en not_active IP Right Cessation
- 2003-05-30 US US10/448,854 patent/US6897216B2/en not_active Expired - Lifetime
2004
- 2004-08-06 US US10/912,834 patent/US7067655B2/en not_active Expired - Lifetime
2006
- 2006-05-02 JP JP2006128415A patent/JP4938348B2/en not_active Expired - Lifetime
2007
- 2007-03-16 JP JP2007069618A patent/JP2007145875A/en not_active Withdrawn
2012
- 2012-04-06 US US13/441,140 patent/USRE44205E1/en not_active Expired - Lifetime
- 2012-06-04 IL IL220174A patent/IL220174A/en active IP Right Grant

Also Published As

Publication number	Publication date
CZ20023886A3 (en)	2003-02-12
SK287748B6 (en)	2011-08-04
IL152726A (en)	2012-07-31
CN1800186A (en)	2006-07-12
HU230420B1 (en)	2016-05-30
WO2001092264A1 (en)	2001-12-06
EP1283839A1 (en)	2003-02-19
CN1247588C (en)	2006-03-29
US20050026932A1 (en)	2005-02-03
HK1049007A1 (en)	2003-04-25
AR028621A1 (en)	2003-05-14
NO20025651D0 (en)	2002-11-25
BR0111015A (en)	2005-01-11
EP1283839B1 (en)	2005-04-20
US20020099061A1 (en)	2002-07-25
TWI288137B (en)	2007-10-11
PT1283839E (en)	2005-08-31
JP2006219497A (en)	2006-08-24
ATE293627T1 (en)	2005-05-15
CZ303790B6 (en)	2013-05-09
BRPI0111015B1 (en)	2017-11-07
ECSP024364A (en)	2003-03-31
DE60110219T2 (en)	2006-03-09
NZ522326A (en)	2006-03-31
NO20025651L (en)	2003-01-23
NO325008B1 (en)	2008-01-14
HK1049007B (en)	2005-09-16
RU2315053C2 (en)	2008-01-20
KR20030003746A (en)	2003-01-10
PL360472A1 (en)	2004-09-06
HUP0600239A3 (en)	2008-06-30
SI1283839T1 (en)	2005-08-31
MY132006A (en)	2007-09-28
BRPI0111015B8 (en)	2021-05-25
US20040023997A1 (en)	2004-02-05
JP4574112B2 (en)	2010-11-04
ES2237576T3 (en)	2005-08-01
MXPA02011625A (en)	2003-03-27
PE20020062A1 (en)	2002-02-02
HUP0600239A2 (en)	2006-07-28
IL220174A0 (en)	2012-07-31
AU6808901A (en)	2001-12-11
US6897216B2 (en)	2005-05-24
AU2001268089C1 (en)	2006-04-13
DK1283839T3 (en)	2005-07-25
DE60110219D1 (en)	2005-05-25
SK16712002A3 (en)	2003-08-05
IL220174A (en)	2015-07-30
CA2410237C (en)	2008-01-08
KR100520907B1 (en)	2005-10-11
JP2007145875A (en)	2007-06-14
ZA200208898B (en)	2004-03-01
CN1451007A (en)	2003-10-22
US7067655B2 (en)	2006-06-27
JP4938348B2 (en)	2012-05-23
USRE44205E1 (en)	2013-05-07
US6630475B2 (en)	2003-10-07
CA2410237A1 (en)	2001-12-06
JP2003535094A (en)	2003-11-25
AU2001268089B2 (en)	2005-04-28
PL218764B1 (en)	2015-01-30
CN100384847C (en)	2008-04-30

Publication	Publication Date	Title
AU6808901A (en)	2001-12-11	Adenosine a2a receptor antagonists
IL161572A0 (en)	2004-09-27	Adenosine a2a receptor antagonists
HK1063780A1 (en)	2005-01-14	Adenosine a2a receptor antagonists
HUP0401925A3 (en)	2007-05-29	A2b adenosine receptor antagonists
IL155712A0 (en)	2003-11-23	Aminothiazoles and their use as adenosine receptor antagonists
IL147198A0 (en)	2002-08-14	N-pyrazole a2a receptor agonists
IL147195A0 (en)	2002-08-14	C-pyrazole a2a receptor agonists
HUP0401437A3 (en)	2007-05-29	Adenosine a3 receptor agonists
IL175759A0 (en)	2006-09-05	A2b adenosine receptor antagonists
IL150912A0 (en)	2003-02-12	Adenosine receptor modulators
HK1064097A1 (en)	2005-01-21	Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
IL156046A0 (en)	2003-12-23	Condensed purine derivatives as a1 adenosine receptor antagonists
NO20020979D0 (en)	2002-02-27	Selective A2B adenosine receptor antagonists
AU3167402A (en)	2002-06-24	Aminotriazolopyridiine derivatives as adenosine receptor ligands
HK1047750A1 (en)	2003-03-07	Chemokine receptor antagonists
GB0000474D0 (en)	2000-03-01	Receptor
AU1252102A (en)	2002-05-21	Receptor
SI1444233T1 (en)	2011-11-30	A2b adenosine receptor antagonists
SI1401837T1 (en)	2006-02-28	Purine derivatives as a2b adenosine receptor antagonists
GB0010292D0 (en)	2000-06-14	A adenosine receptor agonists
GB0014761D0 (en)	2000-08-09	Receptor
GB0009269D0 (en)	2000-05-31	Receptor
GB0031096D0 (en)	2001-01-31	Receptor
HUP0203369A3 (en)	2004-12-28	Polycycloalkylpurines as adenosine receptor antagonists, process for their preparation and their use